ATE404199T1 - Verwendung von naloxon zur behandlung von essstörungen - Google Patents
Verwendung von naloxon zur behandlung von essstörungenInfo
- Publication number
- ATE404199T1 ATE404199T1 AT06396001T AT06396001T ATE404199T1 AT E404199 T1 ATE404199 T1 AT E404199T1 AT 06396001 T AT06396001 T AT 06396001T AT 06396001 T AT06396001 T AT 06396001T AT E404199 T1 ATE404199 T1 AT E404199T1
- Authority
- AT
- Austria
- Prior art keywords
- eating
- naloxone
- responses
- eating disorders
- bulimia
- Prior art date
Links
- 208000030814 Eating disease Diseases 0.000 title abstract 6
- 208000019454 Feeding and Eating disease Diseases 0.000 title abstract 6
- 235000014632 disordered eating Nutrition 0.000 title abstract 6
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 title abstract 4
- 229960004127 naloxone Drugs 0.000 title abstract 4
- 230000004044 response Effects 0.000 abstract 4
- 208000032841 Bulimia Diseases 0.000 abstract 3
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 2
- 230000008033 biological extinction Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 206010004716 Binge eating Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 208000014679 binge eating disease Diseases 0.000 abstract 1
- 235000005686 eating Nutrition 0.000 abstract 1
- 230000020595 eating behavior Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 230000002650 habitual effect Effects 0.000 abstract 1
- 230000036651 mood Effects 0.000 abstract 1
- 235000020830 overeating Nutrition 0.000 abstract 1
- 230000002787 reinforcement Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/031,534 US7910599B2 (en) | 2005-01-10 | 2005-01-10 | Method for treating eating disorders by selective extinction with transdermal naloxone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE404199T1 true ATE404199T1 (de) | 2008-08-15 |
Family
ID=36123036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06396001T ATE404199T1 (de) | 2005-01-10 | 2006-01-10 | Verwendung von naloxon zur behandlung von essstörungen |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7910599B2 (de) |
| EP (1) | EP1681057B1 (de) |
| AT (1) | ATE404199T1 (de) |
| DE (1) | DE602006002135D1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8627816B2 (en) | 2011-02-28 | 2014-01-14 | Intelliject, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
| US9192570B2 (en) | 2013-12-20 | 2015-11-24 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| US10085937B2 (en) | 2014-03-14 | 2018-10-02 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| CN106163499A (zh) | 2014-03-14 | 2016-11-23 | 欧皮安特制药有限公司 | 鼻用药物产品及其使用方法 |
| US9561177B2 (en) | 2014-03-14 | 2017-02-07 | Adapt Pharma Limited | Nasal drug products and methods of their use |
| US9480644B2 (en) | 2014-03-14 | 2016-11-01 | Opiant Pharmaceuticals, Inc. | Nasal drug products and methods of their use |
| US11135155B2 (en) | 2014-07-08 | 2021-10-05 | Hikma Pharmaceuticals Usa Inc. | Liquid naloxone spray |
| US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
| CN111447927A (zh) * | 2017-12-08 | 2020-07-24 | 帝国制药美国公司 | 纳洛酮经皮给药装置及其使用方法 |
| WO2021163252A1 (en) | 2020-02-14 | 2021-08-19 | Teikoku Pharma Usa, Inc. | Topical naloxone compositions and methods for using the same |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217353A (en) | 1978-05-19 | 1980-08-12 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia |
| US4477457A (en) | 1982-10-28 | 1984-10-16 | E. I. Du Pont De Nemours And Company | Method for inducing anorexia using nalmetrene |
| US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
| US4546103A (en) | 1984-09-18 | 1985-10-08 | Huebner Hans F | Method of treating weight loss disorders |
| US4882335A (en) | 1988-06-13 | 1989-11-21 | Alko Limited | Method for treating alcohol-drinking response |
| US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
| US5587381A (en) | 1995-03-27 | 1996-12-24 | Sinclair; John D. | Method for terminating methadone maintenance through extinction of the opiate-taking responses |
| DE19605590A1 (de) * | 1996-02-15 | 1997-08-21 | Inresa Arzneimittel Gmbh | Verwendung eines transdermalen therapeutischen Naloxon-Systems (Naloxon TTS) |
| US5780479A (en) | 1997-04-04 | 1998-07-14 | Regents Of The University Of Minnesota | Use of opioid antagonists to treat impulse-control disorders |
| US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
-
2005
- 2005-01-10 US US11/031,534 patent/US7910599B2/en not_active Expired - Fee Related
-
2006
- 2006-01-10 EP EP06396001A patent/EP1681057B1/de not_active Expired - Lifetime
- 2006-01-10 AT AT06396001T patent/ATE404199T1/de not_active IP Right Cessation
- 2006-01-10 DE DE602006002135T patent/DE602006002135D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006002135D1 (de) | 2008-09-25 |
| US7910599B2 (en) | 2011-03-22 |
| EP1681057A1 (de) | 2006-07-19 |
| US20060154946A1 (en) | 2006-07-13 |
| EP1681057B1 (de) | 2008-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| ATE417928T1 (de) | Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind. | |
| MY148985A (en) | 2-aminopyridine analogs as glucokinase activators | |
| TW200740804A (en) | Glucokinase activators | |
| ATE521608T1 (de) | Glucokinaseaktivatoren | |
| DE60216139D1 (de) | Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen | |
| ATE427759T1 (de) | Behandlung von fettsucht und verbundenen erkrankungen | |
| WO2008118718A3 (en) | 2-aminopyridine analogs as glucokinase activators | |
| ATE452652T1 (de) | Behandlung neurologischer und neuropsychiatrischer erkrankungen mit botulinumtoxin | |
| DE602005019144D1 (de) | Verfahren zur schmerzbehandlung in knochenkrebs du | |
| DE602006009834D1 (de) | Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung | |
| ATE404199T1 (de) | Verwendung von naloxon zur behandlung von essstörungen | |
| DE602005026724D1 (de) | Verfahren zur verwendung von aus fettgewebe stammenden zellen bei der behandlung von herz-kreislauf-leiden | |
| ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
| DE602005008241D1 (de) | Zusammensetzung mit einem survivin-antisense-oligonucleotid und gemcitabin zur behandlung von krebs | |
| ATE534649T1 (de) | Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 | |
| ATE525480T1 (de) | Verwendung von a33-antigenen und jam-it | |
| ATE515268T1 (de) | Verwendung von op-1 zur behandlung von knorpeldefekten | |
| DE60234708D1 (de) | Behandlung von sti571-resistenter oder -intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen | |
| ATE484291T1 (de) | Behandlung von neurologischen störungen mit hämatopoetischen wachstumsfaktoren | |
| DE602006006068D1 (de) | Verwendung von botulintoxin zur verbesserung der magenentleerung und/oder behandlung von gerd | |
| WO2005115548A3 (en) | Treating depressive disorders with carbonic anhydrase activators | |
| DE602005008013D1 (de) | Ctgf als zielmolekül in der behandlung von mikroalbuminurie in patienten mit diabetischer nephropathie | |
| DE602005020178D1 (de) | 5,6,7-trihydroxyheptansäure und analoge zur behandlung von augenkrankheiten und mit hyperproliferativen und angiogenen reaktionen verbundenen krankheiten | |
| DE602006015373D1 (de) | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |